Statins are grouped by how much they lower LDL cholesterol rather than by brand name. Guidelines define three intensity classes, low for reductions under thirty percent, moderate for thirty to forty nine, and high for fifty percent or more. Enter the percentage reduction you need and the tool identifies the matching class, which the article then translates into typical drug and dose examples.
Your visual report appears here
Fill in the form and press Calculate. You will get your number, an interpretation chip, and a personalized chart pack drawn instantly in your browser.
- Risk spectrum with your position marked
- Reference ranges from the original publication
- Shareable link, nothing stored
Scientific references
The 2013 American guideline abandoned the old treat to target habit and instead asked a simpler question, how much LDL reduction does this patient need. Statins were then sorted into three classes by their average lowering power, which freed clinicians from memorizing dose tables and focused attention on the percentage that matters.
The Three Classes
Low intensity therapy lowers LDL by less than thirty percent and covers small doses of most agents, useful for older patients or those prone to side effects. Moderate intensity achieves thirty to forty nine percent and includes atorvastatin ten to twenty milligrams and rosuvastatin five to ten. High intensity reaches fifty percent or more with atorvastatin forty to eighty or rosuvastatin twenty to forty milligrams daily.
Matching Class to Patient
Anyone with established vascular disease generally starts at high intensity, because trials show events falling with deeper reductions. Primary prevention in diabetics aged forty to seventy five typically begins with moderate intensity, rising if risk enhancers accumulate. When the maximum tolerated statin still falls short, ezetimibe adds another fifteen to twenty percent, and PCSK9 inhibitors can halve LDL again on top.
Doubling Dose Gains Little
A quirk worth knowing is the rule of six. Each doubling of a statin dose adds only about six percent further LDL reduction, while side effect risk climbs faster. That arithmetic is why combination therapy often beats simply pushing one drug to its ceiling.
Muscle aches affect a minority of users and usually resolve with a switch of agent or dosing schedule. True intolerance is rarer than reported, so structured rechallenge under medical guidance often finds a workable regimen before anyone gives up on this drug class entirely.